Calcimedica announces first patient enrolled in international expansion of carpo trial of auxora™ in acute pancreatitis (ap)

Carpo top-line data expected in 1h2024 carpo enrolling in over 30 sites in the us and india la jolla, calif., aug. 09, 2023 (globe newswire) -- calcimedica inc. (“calcimedica”) (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that its ongoing carpo trial, a phase 2b trial evaluating auxora™ for the treatment of acute pancreatitis (ap) with accompanying systemic inflammatory response syndrome (sirs), was expanded to clinical research sites in india and that the first patient has been enrolled there.
CALC Ratings Summary
CALC Quant Ranking